Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate.During the first 12 days of December, shares of uniQure rocketed 152% higher, and investors want to know if this stock has legs that can propel it further in 2025. Let's weigh the positive news that drove the stock through the roof against some challenges the drugmaker faces to see if it's a smart stock to buy now.Shares of uniQure surged on Dec. 10 after the company gave investors great news regarding AMT-130, an experimental gene therapy it's developing to treat Huntington's disease. According to uniQure, the agency is willing to review an application for accelerated approval based on an ongoing pair of phase 1/2 clinical trials.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool